D
Donald A. Berry
Researcher at University of Texas MD Anderson Cancer Center
Publications - 449
Citations - 43822
Donald A. Berry is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 85, co-authored 423 publications receiving 38595 citations. Previous affiliations of Donald A. Berry include University of Minnesota & University of Illinois at Chicago.
Papers
More filters
Journal ArticleDOI
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.
Amy S. Clark,Christina Yau,Denise M. Wolf,Emanuel F. Petricoin,Laura J. van't Veer,Douglas Yee,Stacy L. Moulder,Anne M. Wallace,A. Jo Chien,Claudine Isaacs,Judy C. Boughey,Kathy S. Albain,Kathleen Kemmer,Barbara Haley,Hyo S. Han,Andres Forero-Torres,Anthony D. Elias,Julie E. Lang,Erin D. Ellis,Rachel L. Yung,Debu Tripathy,Rita Nanda,Julia Wulfkuhle,Lamorna Brown-Swigart,Rosa I. Gallagher,Teresa Helsten,Erin Roesch,Cheryl Ewing,Michael Alvarado,Erin P. Crane,Meredith Buxton,Julia L. Clennell,Melissa Paoloni,Smita Asare,Amy Wilson,Gillian L. Hirst,Ruby Singhrao,Katherine Steeg,Adam Asare,Jeffrey B. Matthews,Scott M. Berry,Ashish Sanil,Michelle E. Melisko,Jane Perlmutter,Hope S. Rugo,Richard Schwab,W. Fraser Symmans,Nola M. Hylton,Donald A. Berry,Laura J. Esserman,Angela DeMichele +50 more
TL;DR: In this paper, the authors presented the efficacy and biomarker analysis of two HER2-targeted combinations in the context of the neoadjuvant I-SPY2 phase 2 adaptive platform trial for early breast cancer at high risk of recurrence.
Journal ArticleDOI
Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL
Julia Wulfkuhle,Christina Yau,Denise M. Wolf,Daniel J. Vis,Rosa I. Gallagher,Lamorna Brown-Swigart,Gillian L. Hirst,Emile E. Voest,Angela DeMichele,Nola M. Hylton,Fraser Symmans,Douglas Yee,Laura J. Esserman,Donald A. Berry,Minetta C. Liu,John W. Park,Lodewyk F. A. Wessels,Laura J. van't Veer,Emanuel F. Petricoin +18 more
TL;DR: Activation of HER family phosphoproteins associates with response to neratinib, but only EGFR Y1173 and STMN1 appear to add value to the graduating signature, which implies that there is a subset of patients with TN disease who paradoxically exhibit HER family signaling activation and may achieve clinical benefit with Neratinib.
Journal ArticleDOI
Advancing Clinical Trials to Streamline Drug Development.
Susan E. Bates,Donald A. Berry,Sanjeeve Balasubramaniam,Stuart Bailey,Patricia LoRusso,Eric H. Rubin +5 more
TL;DR: The last decade in oncology has been marked by the identification of numerous new potential cancer targets and even more agents designed to inhibit them, and many challenges remain, including the lack of predictability of preclinical data for clinical results and phase II data for phase III results.
Journal ArticleDOI
Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues
David L. Rimm,Torsten O. Nielsen,Scott D. Jewell,Daniel C. Rohrer,Gloria Broadwater,Frederic M. Waldman,Kisha A. Mitchell,Baljit Singh,Gregory J. Tsongalis,Wendy L. Frankel,Anthony M. Magliocco,Jonathan F. Lara,Eric D. Hsi,Ira J. Bleiweiss,Sunil Badve,Beiyun Chen,Peter M. Ravdin,Richard L. Schilsky,Ann D. Thor,Donald A. Berry +19 more
TL;DR: Members of the Cancer and Leukemia Group B Pathology Committee relay their experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies and discuss statistical issues arising from having a proportion of patients available for TMAs.
Journal ArticleDOI
Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.
Oguzhan Alagoz,Donald A. Berry,Harry J. de Koning,Eric J. Feuer,Sandra J. Lee,Sylvia K. Plevritis,Clyde B. Schechter,Natasha K. Stout,Amy Trentham-Dietz,Jeanne S. Mandelblatt +9 more
TL;DR: An overview and history of the CISNET breast cancer models is provided, an overview of the major changes in the model inputs over time, and examples for how CISNET Breast Cancer Working Group models have been used for policy evaluation are presented.